Latest news with #FRSA
South Wales Argus
4 days ago
- Health
- South Wales Argus
NHS patient care starts with caring for colleagues
That is why we need to talk honestly about something that doesn't often make the headlines: culture. Behind every decision, diagnosis, or delay, there are human beings, both patients and staff, doing their best in a system under strain. But when the workplace culture is poor, fearful, rushed, dismissive, that strain becomes something more dangerous. It becomes unsafe. Maria's Movement is a stark example. In the final chapter of her life, Maria didn't receive the care she needed. Her family's concerns were brushed aside. Consultants assumed they knew best. And the staff around her, though well-intentioned, were afraid to speak up or challenge decisions. It wasn't a lack of skill or kindness. It was the culture. Culture isn't a buzzword. It is the invisible thread that shapes how people behave when the pressure is on. It's whether staff feel safe to speak up. Whether people are listened to. Whether the patient and their family feel like they matter. And when that thread unravels, care suffers. When NHS staff feel respected, supported and able to raise concerns, patients get better care. When staff are burnt out, fearful, or ignored, the risk of harm rises, and so does the heartbreak. I began my NHS career more than 30 years ago in South Wales. I wasn't clinical, I worked in admin, but even then, there was an unspoken standard: you care for every patient like they are a member of your family. You felt it in the way teams treated each other, in the pride they took in their work. That spirit shaped everything. Today, we need to bring that spirit back not just through posters or pledges, but by changing the conditions staff work in. That means creating real psychological safety. Listening with humility. And treating staff wellbeing as essential to patient safety, not an optional extra. When we care better for our staff, staff care better for our patients. It really is that simple. We're living through a time of huge change in the NHS. But no matter how much the system evolves, one thing must stay the same: people deserve to be treated with dignity, compassion, and respect on both sides of the bed. The culture of our healthcare system isn't a background issue. It is the care. And when we get that right, we all feel the difference. Liza Collins, MA, FRSA, is Future of Healthcare Executive Leadership Coach and NHS Leadership Academy Executive Coach.
Zawya
04-03-2025
- Business
- Zawya
Taranis Capital secures DFSA licence
Dubai, UAE: Taranis Capital Ltd, an ethical, fintech-focused investment company, has secured a licence from the Dubai Financial Services Authority (DFSA), the independent regulator of financial services within Dubai International Financial Centre (DIFC). This milestone significantly strengthens the firm's ability to expand its operations and deliver innovative financial solutions with confidence and integrity. At the same time, the firm welcomes Dr Bijna Kotak Dasani MBE, FRSA as Chief Investment Officer (CIO), strengthening its leadership as it expands its financial services under robust regulatory oversight. Obtaining the DFSA licence follows an intensive 18-month regulatory process, reflecting Taranis Capital's commitment to governance, compliance and operational excellence. The licence reinforces the firm's position within DIFC, enabling it to broaden its financial services while maintaining the highest regulatory standards. 'Securing our DFSA licence is a huge step forward for Taranis Capital,' said Nicholas Bingham, founding partner and CEO of Taranis Capital. 'It's been an intense process, but one that highlights our dedication to doing things the right way. This achievement gives us a strong foundation to grow, innovate and continue delivering exceptional financial solutions for our clients.' 'We are proud to be operating under the DFSA's robust regulatory framework, which reinforces trust in our business and enables us to serve our clients with the highest standards of governance and transparency.' Alongside this regulatory achievement, Taranis Capital Ltd is delighted to welcome Dr Bijna Kotak Dasani MBE, FRSA as Chief Investment Officer. A highly respected leader in global financial services, Dr Dasani brings 25 years of experience across investment banking, venture capital and entrepreneurship. She has held senior roles at some of Wall Street's leading firms, advised monarchies and serves on multiple global venture capital investment committees. An alumna of the University of Oxford and De Montfort University, Dr Dasani also holds venture capital certifications from UC Berkeley Law, Venture Forward, NVCA, and Newton. She is a Fellow of the Royal Society of Arts, Manufactures and Commerce (FRSA) and has received numerous industry accolades. Her achievements include being named among Fortune India's Most Dynamic Personalities (2022), Fox Story India's Woman Face of the Year (2023), and one of Yahoo Finance's Top 100 Women Executives globally. In 2020, she was appointed a Member of the Most Excellent Order of the British Empire (MBE) by Her Majesty, The Late Queen Elizabeth II. She is also a published author, contributing to books on leadership, finance and innovation. Speaking about her new role, Dr Dasani said: "I am honoured to join Taranis Capital Ltd at such a pivotal moment. The firm's commitment to regulatory excellence, innovation and client-centric solutions aligns perfectly with my passion for driving impactful financial strategies. I look forward to contributing to Taranis Capital's growth and long-term success." With this leadership appointment and licence, Taranis Capital Ltd is well-placed to strengthen its presence in DIFC and expand its offering of innovative financial solutions. For media enquiries, please contact Nicholas Bingham Taranis Capital Ltd nicholas@ Nigel Sillitoe CEO, Insight Discovery Email: sillitoe@ About Taranis Capital Ltd Taranis Capital Ltd is a financial services firm based in the Dubai International Financial Centre (DIFC), specialising on investing in fintechs with excellent ethical governance. With a strong focus on regulatory compliance and client-centric solutions, the firm is committed to delivering excellence in the financial sector. About the DFSA The Dubai Financial Services Authority (DFSA) is the independent regulator of financial services conducted in or from the DIFC. It upholds international best practices to foster a transparent, secure, and well-regulated financial environment.
Yahoo
27-02-2025
- Business
- Yahoo
MannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Release Date: February 26, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MannKind Corp (NASDAQ:MNKD) reported a 31% increase in fourth-quarter revenues, reaching $77 million, and a 43% increase for the full year, totaling $286 million. The company successfully reduced its debt principal by $236 million in 2024, ending the year with a strong cash position of $203 million. MannKind Corp (NASDAQ:MNKD) achieved record revenues in its endocrine business unit, with Q4 revenue of $23 million and full-year revenue of $82 million. The company has two FDA-approved products on its technosphere platform and is advancing its pipeline with promising candidates like clofazimine inhalation suspension and techev DPI. MannKind Corp (NASDAQ:MNKD) announced a collaboration with Anasstar, enabling the promotion of Maximi through its US sales force, which is expected to enhance its pediatric footprint. The company faces challenges in launching its pediatric indication, with approval not expected until early 2026. Vigo net revenue decreased by 4% over the prior year, and the salesforce is no longer actively promoting the product. Despite the progress, MannKind Corp (NASDAQ:MNKD) anticipates potential delays in its India launch due to packaging and shipping issues. The company is still working on expanding its institutional selling capabilities, which is crucial for its future growth in the pediatric market. MannKind Corp (NASDAQ:MNKD) acknowledges the need for significant investments in its FRSA business, which could impact margins in the near term. Warning! GuruFocus has detected 4 Warning Signs with MNKD. Q: Can you talk about how we should be thinking about margins over the next few quarters, given the investments planned in the FRSA business? A: (Chris Prentice, CFO) Our margins have improved due to the utilization of our manufacturing plant with the build-up of Tibeso DPI and FRSA. These margins are expected to remain steady going forward. Q: Can you provide more details on the gross to net discounting and rebates for DPI this quarter, and what are the next steps for DPI and IPF? A: (Michael Casanna, CEO) The new norm for gross to net discounting is expected to be consistent with Q4. Regarding DPI and IPF, we have a meeting in Q2 to discuss the bridging study, which is necessary for the US filing. We anticipate these discussions to accelerate soon. Q: How are you balancing operational profitability with investment in the pediatric launch for FRSA? A: (Michael Casanna, CEO) We have capital to deploy and aim to invest in areas that drive the best return for shareholders. The focus is on launching pediatrics appropriately, alongside ongoing trials for clofazamine and tetanus. Q: What are the critical success factors for the potential launch of FRSA in pediatrics, and how will the agreement with CIPLA in India contribute to FRSA's topline? A: (Michael Casanna, CEO) Key success factors include ensuring a best-in-class reimbursement hub, institutional selling capabilities, and education and awareness. For CIPLA, we expect to ship our first order by the end of the year, which could improve manufacturing efficiency and COGS. Q: Regarding the interim analysis for 101, will it look at both co-primary endpoints, and how might the study size change? A: (Michael Casanna, CEO) The interim analysis will occur after 100 patients reach their 6-month endpoint. We anticipate the study size could increase from 180 to 300 patients, and we aim to maintain statistically valid results between the placebo and active arm. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
